Antimalarial activity of sera from subjects taking HIV protease inhibitors

AIDS. 2007 Mar 30;21(6):763-5. doi: 10.1097/QAD.0b013e328031f41a.

Abstract

Synergy between HIV and malaria is being increasingly recognized. We examined the antimalarial activity of sera from subjects receiving chloroquine, no drugs or HAART. Sera from subjects taking ritonavir-boosted saquinavir or lopinavir significantly inhibited parasite growth (median of 55 and 69% inhibition, respectively). These results indicate that patients on protease inhibitors may be afforded some protection from malaria. The clinical relevance of these observations will require confirmation in controlled studies in malaria-endemic regions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods
  • Chloroquine / therapeutic use
  • Drug Synergism
  • HIV Infections / blood
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Lopinavir
  • Malaria, Falciparum / blood
  • Malaria, Falciparum / complications
  • Malaria, Falciparum / drug therapy*
  • Plasmodium falciparum / drug effects
  • Plasmodium falciparum / growth & development
  • Pyrimidinones / therapeutic use
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / therapeutic use
  • Saquinavir / therapeutic use
  • Treatment Outcome

Substances

  • Antimalarials
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • Chloroquine
  • Saquinavir
  • Ritonavir